{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:29:12Z","timestamp":1792517352753,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175023","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T03:19:44Z","timestamp":1652411984000},"page":"175023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Update of treatment for Gaucher disease"],"prefix":"10.1016","volume":"926","author":[{"given":"Weijing","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175023_bib1","series-title":"Zavesca\u00ae","year":"2021"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcmd.2005.05.007","article-title":"Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations","volume":"35","author":"Alfonso","year":"2005","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-017-1541-7","article-title":"Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports","volume":"12","author":"Amato","year":"2018","journal-title":"J. Med. Case Rep."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10545-014-9725-4","article-title":"Long term differential consequences of miglustat therapy on intestinal disaccharidases","volume":"37","author":"Amiri","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejphar.2022.175023_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175023_bib6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tig.2018.05.004","article-title":"Gene editing on center stage","volume":"34","author":"Bak","year":"2018","journal-title":"Trends Genet."},{"issue":"21","key":"10.1016\/j.ejphar.2022.175023_bib7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175023_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nbd.2015.10.011","article-title":"Mitochondrial fusion\/fission dynamics in neurodegeneration and neuronal plasticity","volume":"90","author":"Bertholet","year":"2016","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib9","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme replacement in Gaucher disease","volume":"1","author":"Beutler","year":"2004","journal-title":"PLoS Med."},{"issue":"4","key":"10.1016\/j.ejphar.2022.175023_bib10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/mt.2011.289","article-title":"Retroviral integrations in gene therapy trials","volume":"20","author":"Biasco","year":"2012","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175023_bib11","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1172\/JCI105417","article-title":"Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease","volume":"45","author":"Brady","year":"1966","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175023_bib12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1528-1167.2007.01074.x","article-title":"Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase\/miglustat combination","volume":"48","author":"Capablo","year":"2007","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ejphar.2022.175023_bib13","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1534\/genetics.111.131433","article-title":"Genome engineering with zinc-finger nucleases","volume":"188","author":"Carroll","year":"2011","journal-title":"Genetics"},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41573-019-0020-9","article-title":"Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges","volume":"18","author":"Cavazzana","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13256-016-1147-5","article-title":"Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report","volume":"11","author":"Ceravolo","year":"2017","journal-title":"J. Med. Case Rep."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib16","first-page":"327","article-title":"Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state","volume":"14","author":"Chan","year":"1994","journal-title":"Bone Marrow Transplant."},{"issue":"17","key":"10.1016\/j.ejphar.2022.175023_bib17","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1111\/j.1742-4658.2006.05410.x","article-title":"Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients","volume":"273","author":"Chang","year":"2006","journal-title":"FEBS J."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175023_bib18","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1097\/MPH.0000000000002129","article-title":"Successful treatment of Gaucher disease with matched sibling hematopoietic stem cell transplantation: a case report and literature review","volume":"43","author":"Chavananon","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2012.10.010","article-title":"Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage","volume":"62","author":"Cleeter","year":"2013","journal-title":"Neurochem. Int."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175023_bib20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","article-title":"Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III","volume":"31","author":"Cox-Brinkman","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9985","key":"10.1016\/j.ejphar.2022.175023_bib22","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejphar.2022.175023_bib23","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2022.175023_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtm.2020.11.018","article-title":"Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector","volume":"20","author":"Dahl","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejphar.2022.175023_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/srep10903","article-title":"Pharmacological chaperones and coenzyme Q10 treatment improves mutant beta-glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease","volume":"5","author":"de la Mata","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.stem.2012.11.011","article-title":"A TALEN genome-editing system for generating human stem cell-based disease models","volume":"12","author":"Ding","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nmeth.1539","article-title":"Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures","volume":"8","author":"Doyon","year":"2011","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/hum.2018.072","article-title":"Delivery of glucosylceramidase beta gene using AAV9 vector therapy as a treatment strategy in mouse models of Gaucher disease","volume":"30","author":"Du","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"17","key":"10.1016\/j.ejphar.2022.175023_bib29","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","article-title":"Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation","volume":"9","author":"Dunbar","year":"1998","journal-title":"Hum. Gene Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175023_bib30","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"issue":"37","key":"10.1016\/j.ejphar.2022.175023_bib31","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2022.175023_bib32","series-title":"3 Studies Found for: Ambroxol | Gaucher Disease","year":"2021"},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib34","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.87.6.2334","article-title":"Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease","volume":"87","author":"Fink","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2022.175023_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.scr.2017.07.009","article-title":"Generation of a homozygous GBA deletion human embryonic stem cell line","volume":"23","author":"G\u00fcndner","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.ejphar.2022.175023_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcmd.2016.10.017","article-title":"Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: the Spanish ZAGAL project","volume":"68","author":"Giraldo","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejphar.2022.175023_bib37","first-page":"13","article-title":"Gaucher disease and other storage disorders","volume":"2012","author":"Grabowski","year":"2012","journal-title":"Am. Soc. Hematol Educ"},{"key":"10.1016\/j.ejphar.2022.175023_bib38","doi-asserted-by":"crossref","first-page":"116636","DOI":"10.1016\/j.lfs.2019.116636","article-title":"CRISPR-Cas9 system: a new-fangled dawn in gene editing","volume":"232","author":"Gupta","year":"2019","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib39","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10446","article-title":"Non-immune hemolysis in Gaucher disease and review of the literature","volume":"12","author":"Hershkop","year":"2021","journal-title":"Rambam Maimonides Med J"},{"issue":"8542","key":"10.1016\/j.ejphar.2022.175023_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(87)91673-4","article-title":"Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome","volume":"1","author":"Hobbs","year":"1987","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejphar.2022.175023_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/pds.1779","article-title":"Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme","volume":"18","author":"Hollak","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"10.1016\/j.ejphar.2022.175023_bib42","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10038-004-0186-8","article-title":"Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector","volume":"49","author":"Hong","year":"2004","journal-title":"J. Hum. Genet."},{"issue":"8962","key":"10.1016\/j.ejphar.2022.175023_bib43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(95)92597-X","article-title":"Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation","volume":"345","author":"Hoogerbrugge","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175023_bib44","author":"Inacio"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08880018.2012.762076","article-title":"Gauchers disease-a reappraisal of hematopoietic stem cell transplantation","volume":"30","author":"Ito","year":"2013","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ejphar.2022.175023_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247211","article-title":"Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease","volume":"16","author":"Ivanova","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175023_bib47","author":"Iyer"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s10038-019-0704-3","article-title":"Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease","volume":"65","author":"Jiang","year":"2020","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejphar.2022.175023_bib49","doi-asserted-by":"crossref","first-page":"173562","DOI":"10.1016\/j.ejphar.2020.173562","article-title":"Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome)","volume":"888","author":"Kong","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/cells10020420","article-title":"Potential treatment of lysosomal storage disease through modulation of the mitochondrial-lysosomal axis","volume":"10","author":"Kuk","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","article-title":"Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study","volume":"51","author":"Kuter","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejphar.2022.175023_bib52","first-page":"100652","article-title":"Allogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease","volume":"25","author":"Lee","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbadis.2004.03.007","article-title":"N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease","volume":"1689","author":"Lin","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"35","key":"10.1016\/j.ejphar.2022.175023_bib54","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/v3060677","article-title":"Gammaretroviral vectors: biology, technology and application","volume":"3","author":"Maetzig","year":"2011","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.ejphar.2022.175023_bib56","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/hmg\/ddz317","article-title":"Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes","volume":"29","author":"Massaro","year":"2020","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175023_bib57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"issue":"6972","key":"10.1016\/j.ejphar.2022.175023_bib58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib59","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jgm.901","article-title":"AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease","volume":"8","author":"McEachern","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ejphar.2022.175023_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcmd.2018.04.001","article-title":"Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1","volume":"71","author":"Mistry","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"issue":"21","key":"10.1016\/j.ejphar.2022.175023_bib61","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1093\/nar\/gkr597","article-title":"A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity","volume":"39","author":"Mussolino","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/stem.1835","article-title":"Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes","volume":"33","author":"Naphade","year":"2015","journal-title":"Stem Cell."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1172\/JCI115868","article-title":"Retroviral-mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow","volume":"90","author":"Nolta","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"23","key":"10.1016\/j.ejphar.2022.175023_bib65","doi-asserted-by":"crossref","first-page":"11332","DOI":"10.1073\/pnas.89.23.11332","article-title":"Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector","volume":"89","author":"Ohashi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib66","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metabol."},{"issue":"4 Suppl. 5","key":"10.1016\/j.ejphar.2022.175023_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin. Hematol."},{"issue":"9","key":"10.1016\/j.ejphar.2022.175023_bib68","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.3390\/ijms21093268","article-title":"CRISPR\/Cas9 editing for gaucher disease modelling","volume":"21","author":"Pavan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175023_bib69","author":"Phelan"},{"issue":"6","key":"10.1016\/j.ejphar.2022.175023_bib70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1566523214666140918101725","article-title":"TALEN-mediated generation and genetic correction of disease-specific human induced pluripotent stem cells","volume":"14","author":"Ramalingam","year":"2014","journal-title":"Curr. Gene Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nmeth.2331","article-title":"Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer","volume":"10","author":"Ranzani","year":"2013","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.ejphar.2022.175023_bib72","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.15402","article-title":"How we manage Gaucher Disease in the era of choices","volume":"182","author":"Revel-Vilk","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-198807000-00011","article-title":"Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease","volume":"46","author":"Ringden","year":"1988","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/hum.2012.229","article-title":"Biosafety features of lentiviral vectors","volume":"24","author":"Schambach","year":"2013","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib77","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1038\/s41467-020-17148-x","article-title":"Engineering monocyte\/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing","volume":"11","author":"Scharenberg","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ejphar.2022.175023_bib78","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"issue":"15","key":"10.1016\/j.ejphar.2022.175023_bib79","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2022.175023_bib80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-016-0413-3","article-title":"Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients","volume":"11","author":"Smid","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.ejphar.2022.175023_bib81","article-title":"Hematopoietic stem cell transplantation for Gaucher disease","volume":"10","author":"Somaraju","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.ejphar.2022.175023_bib82","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/sctm.20-0386","article-title":"Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1","volume":"10","author":"Srikanth","year":"2021","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib83","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metabol."},{"issue":"37","key":"10.1016\/j.ejphar.2022.175023_bib84","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib85","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175023_bib86","series-title":"Long-term Eliglustat Treatment of Gaucher Patients over up to 10 Years","author":"Stulnig","year":"2022"},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib87","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczynski","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib88","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.braindev.2020.06.015","article-title":"Chaperone therapy for molecular pathology in lysosomal diseases","volume":"43","author":"Suzuki","year":"2021","journal-title":"Brain Dev."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib89","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol. Genet. Metabol."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2022.175023_bib90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11010-020-03834-3","article-title":"Gene therapy: a double-edged sword with great powers","volume":"474","author":"Tang","year":"2020","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175023_bib91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-022-02289-7","article-title":"Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)","volume":"17","author":"Titievsky","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejphar.2022.175023_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/1873-3468.14298","article-title":"Mitochondria, energy, and metabolism in neuronal health and disease","author":"Trigo","year":"2022","journal-title":"FEBS Lett."},{"issue":"7586","key":"10.1016\/j.ejphar.2022.175023_bib93","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature17041","article-title":"Protein misfolding in the endoplasmic reticulum as a conduit to human disease","volume":"529","author":"Wang","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib94","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175023_bib95","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175023_bib96","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"issue":"20","key":"10.1016\/j.ejphar.2022.175023_bib97","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1021\/acschemneuro.0c00558","article-title":"Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for Gaucher disease type 3","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"4","key":"10.1016\/j.ejphar.2022.175023_bib98","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1023\/A:1005367328003","article-title":"Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase","volume":"20","author":"Young","year":"1997","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.ejphar.2022.175023_bib99","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2022.175023_bib100","article-title":"Ambroxol chaperone therapy for Gaucher disease type I-associated liver cirrhosis and portal hypertension: a case report","volume":"22","author":"Zhang","year":"2021","journal-title":"Endocr. Metab. Immune Disord. - Drug Targets"},{"key":"10.1016\/j.ejphar.2022.175023_bib101","article-title":"A DNA nanostructure-based neuroprotectant against neuronal apoptosis via inhibiting toll-like receptor 2 signaling pathway in acute ischemic stroke","author":"Zhou","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2022.175023_bib102","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcmd.2016.07.002","article-title":"Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naive patients with Gaucher disease","volume":"78","author":"Zimran","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"1433","key":"10.1016\/j.ejphar.2022.175023_bib103","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1098\/rstb.2003.1272","article-title":"Gaucher disease and the clinical experience with substrate reduction therapy","volume":"358","author":"Zimran","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2022.175023_bib104","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcmd.2016.10.007","article-title":"Treatment-naive Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials","volume":"68","author":"Zimran","year":"2018","journal-title":"Blood Cells Mol. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:00:57Z","timestamp":1757977257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922002849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":102,"alternative-id":["S0014299922002849"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175023","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update of treatment for Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175023"}}